What is it about?
Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody’s therapeutic effect on chronic lymphocytic leukemia.
Featured Image
Why is it important?
It could be a valid treatment option for patients with CLL.
Read the Original
This page is a summary of: Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients, Therapeutics and Clinical Risk Management, July 2017, Dove Medical Press,
DOI: 10.2147/tcrm.s140023.
You can read the full text:
Contributors
The following have contributed to this page
